Compare CTMX & ODC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTMX | ODC |
|---|---|---|
| Founded | 2008 | 1941 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Miscellaneous manufacturing industries |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 977.1M | 895.7M |
| IPO Year | 2015 | 1994 |
| Metric | CTMX | ODC |
|---|---|---|
| Price | $4.90 | $73.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $12.10 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 45.7K |
| Earning Date | 05-11-2026 | 06-04-2026 |
| Dividend Yield | N/A | ★ 1.12% |
| EPS Growth | N/A | ★ 50.45 |
| EPS | N/A | ★ 1.69 |
| Revenue | $76,201,000.00 | ★ $485,572,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | ★ $22.58 | $43.44 |
| Revenue Growth | N/A | ★ 10.97 |
| 52 Week Low | $0.63 | $41.37 |
| 52 Week High | $8.21 | $74.28 |
| Indicator | CTMX | ODC |
|---|---|---|
| Relative Strength Index (RSI) | 54.57 | 68.51 |
| Support Level | $4.02 | $58.40 |
| Resistance Level | $6.20 | N/A |
| Average True Range (ATR) | 0.28 | 1.96 |
| MACD | 0.08 | 0.40 |
| Stochastic Oscillator | 79.15 | 89.80 |
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.